RBC Capital raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $58 from $55 and keeps an Outperform rating on the shares. The timelines for X-TOLE2 remain intact for early 2026, and the firm continues to see a high chance of success at 75% based on prior azetukalner phase 2b and OLE data, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals price target lowered to $44 from $48 at Wells Fargo
- Xenon Pharmaceuticals: Promising Drug Pipeline and Market Potential Drive Buy Rating
- Xenon Pharmaceuticals: Promising Pipeline and Upcoming Catalysts Drive Buy Rating
- Xenon Pharmaceuticals Reports Q3 2025 Financial Results
- Xenon Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating